Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.

Autor: Khadadah FM; Princess Margaret Cancer Centre, Toronto, ON, Canada., Cerquozzi S; Tom Baker Cancer Centre, Calgary, AB, Canada., Olney HJ; Department of Hematology, Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada., Fraga C; QEII Health Sciences, Halifax, NS, Canada., Dudebout J; Kingston General Hospital Center of Southeastern Ontario, Kingston, ON, Canada., Xenocostas A; Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada., Finn N; Centre Hospitalier Universitaire Dr. Georges-L.-Dumont, Moncton, NB, Canada., Ethier V; Sherbrooke University Hospital Center, Sherbrooke, QC, Canada., Savoie ML; Tom Baker Cancer Centre, Calgary, AB, Canada., Busque L; Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada., Jamani K; Tom Baker Cancer Centre, Calgary, AB, Canada., Kuruvilla P; The William Osler Health Center Brampton Civic Hospital, Brampton, ON, Canada., Faught C; The Ottawa Hospital, Ottawa, ON, Canada., Leber B; Department of Medicine, Division of Hematology, Juravinski Cancer Centre, Hamilton, ON, Canada., Kaedbey R; Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Montreal, QC, Canada., Assouline SE; Department of Medicine and Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada., Kim D; Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: dr.dennis.kim@uhn.ca.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2023 Oct; Vol. 133, pp. 107374. Date of Electronic Publication: 2023 Aug 22.
DOI: 10.1016/j.leukres.2023.107374
Abstrakt: Background: Asciminib is a novel drug specifically targeting ABL myristoyl pocket in the ABL1 protein.
Methods: Forty one patients with chronic myeloid leukemia treated with asciminib from 2018 to 2022 were reviewed and analyzed for the efficacy and tolerability of asciminib using real-world experience data.
Results: The median age was 60 years (range 17-90) with a past history of a cardiovascular event in 21 patients (51%). Patients were pretreated with a median of 3 previous tyrosine kinase inhibitors (range 1-5). After a median of 12 months of asciminib (range 3-41), major molecular response (MMR) rate was 39% (n = 11/28) and 42% (n = 5/12) at 6 and 12 months, respectively. Molecular response with 2 log reduction (MR2) was noted in 54% (n = 15/28) and 50% (n = 6/12) at 6 and 12 months. The cumulative incidence of MMR and MR2 was 46.3% and 66% at 12 months. Five patients discontinued asciminib due to treatment failure (n = 3) or thrombocytopenia (n = 2). There were no cardiovascular events. Out of 7 patients treated with high dose asciminib for T315I mutation, 5 patients achieved MMR or deeper response. The event-free survival was 63% at 12 months.
Conclusion: This study confirmed clinical efficacy and tolerability of asciminib with real-world experience.
Competing Interests: Declaration of Competing Interest FK provides consultancy for Novartis, SC provides consultancy and has honoraria for Novartis, Pfizer, BMS, Celgene, Incite. AX, NF and LB has honoraria from Novartis. BL provides consultancy, has honoraria and on the advisory board for Novartis, Pfizer, BMS, Abbvie, and AMGEN. RK is on the advisory boards of Sanofi, FORUS Therapeutics, Belgene, Pfizer and has honoraria from Janssen and BMS. SA gets research funding from Novartis and has consultancy/ honoraria from Genentech/Roche, Astra Zeneca, Novartis, BMS, Jazz, Gilead, Amgen, Beigene, Abbvie, Paladin. DK is a consultant, has received research funding, and honoraria from Pfizer, Sanofi, Paladin, and Novartis. The remaining authors have no conflict of interest.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: